Monopar Therapeutics Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MNPR, updated each market day.
MNPR AI Sentiment
AI sees no strong directional signal for Monopar Therapeutics Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Sector
Exchange
Market Cap
$387,608,748
Cap Tier
Employees
22
Headquarters
WILMETTE, IL
Listed Since
Dec. 19, 2019
Website
MNPR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MNPR Volatility
Monopar Therapeutics Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
